These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 31718346)
1. 20 years of rituximab treatment: what have we learnt? Renner C Future Oncol; 2019 Dec; 15(36):4119-4121. PubMed ID: 31718346 [No Abstract] [Full Text] [Related]
2. Rituximab biosimilars for B-cell lymphomas: a decade of real-world experience from India. Nair R; Radhakrishnan VS; Mallath MK Lancet Haematol; 2021 Aug; 8(8):e548-e549. PubMed ID: 34329574 [No Abstract] [Full Text] [Related]
3. A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma. Torka P; Patel P; Tan W; Wilding G; Bhat SA; Czuczman MS; Lee KP; Deeb G; Neppalli V; Mavis C; Wallace P; Hernandez-Ilizaliturri FJ Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e51-e60. PubMed ID: 29233743 [TBL] [Abstract][Full Text] [Related]
4. Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab. Ku M; Chong G; Hawkes EA Blood Rev; 2017 Jan; 31(1):23-35. PubMed ID: 27568879 [TBL] [Abstract][Full Text] [Related]
5. Increased proportion of CD20+ T cells after rituximab treatment in patient with neuromyelitis optica later diagnosed with lung B-cell lymphoma: A case report. Lee JK; Kwon S; Han JH; Yoon SE; Kim BJ; Kang ES J Neuroimmunol; 2021 Jun; 355():577564. PubMed ID: 33862419 [TBL] [Abstract][Full Text] [Related]
6. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Salles G; Barrett M; Foà R; Maurer J; O'Brien S; Valente N; Wenger M; Maloney DG Adv Ther; 2017 Oct; 34(10):2232-2273. PubMed ID: 28983798 [TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of diffuse large B-cell lymphoma: Impact of biosimilar rituximab and radiation. Ganesan P; Sagar TG; Kannan K; Radhakrishnan V; Rajaraman S; John A; Sundersingh S; Mahajan V; Ganesan TS Indian J Cancer; 2017; 54(2):430-435. PubMed ID: 29469072 [TBL] [Abstract][Full Text] [Related]
8. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Short NJ; Kantarjian HM; Ko H; Khoury JD; Ravandi F; Thomas DA; Garcia-Manero G; Khouri M; Cortes JE; Wierda WG; Verstovsek S; Estrov Z; Ferrajoli A; Thompson PA; Pierce S; O'Brien SM; Jabbour E Am J Hematol; 2017 Jun; 92(6):E114-E117. PubMed ID: 28295472 [No Abstract] [Full Text] [Related]
9. New treatment for non-Hodgkin B-cell lymphomas with a special focus on the impact of junctional adhesion molecules. Imhof BA; Matthes T Swiss Med Wkly; 2017; 147():w14487. PubMed ID: 28944932 [TBL] [Abstract][Full Text] [Related]
10. The use of ofatumumab in the treatment of B-cell malignancies. Soe ZN; Allsup D Future Oncol; 2017 Dec; 13(29):2611-2628. PubMed ID: 28850252 [TBL] [Abstract][Full Text] [Related]
11. Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients. Vijenthira A; Maganti M; Kukreti V; Kuruvilla J; Tiedemann R; Chen C; Crump M; Prica A Leuk Lymphoma; 2019 Oct; 60(10):2576-2579. PubMed ID: 30997853 [No Abstract] [Full Text] [Related]
12. Can rituximab unlock the innate potential of checkpoint blockade in the CNS? Rubenstein JL Leuk Lymphoma; 2019 Feb; 60(2):281-283. PubMed ID: 30188237 [No Abstract] [Full Text] [Related]
13. Rituximab biosimilars in hematologic malignancies: the need for a real-world approach. Nava-Parada P; Shelbaya A; Nabhan C Future Oncol; 2020 Sep; 16(26):2017-2027. PubMed ID: 32598173 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of intensified rituximab induction and maintenance for low grade B cell lymphoma. Nagai H; Shimomura T; Takeuchi M; Hanada S; Komeno T; Sunami K; Hidaka M; Yano T; Kitano K; Yoshida I; Inoue N; Saito A; Horibe K; Motitani S; Ichihara S; Watanabe T; Sawamura M Leuk Lymphoma; 2017 Dec; 58(12):2845-2851. PubMed ID: 28509595 [TBL] [Abstract][Full Text] [Related]
16. Novel Insights into Membrane Targeting of B Cell Lymphoma. de Winde CM; Elfrink S; van Spriel AB Trends Cancer; 2017 Jun; 3(6):442-453. PubMed ID: 28718418 [TBL] [Abstract][Full Text] [Related]
17. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas. Feugier P Future Oncol; 2015; 11(9):1327-42. PubMed ID: 25952779 [TBL] [Abstract][Full Text] [Related]
18. In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis. Salinas-Jazmín N; González-González E; Vásquez-Bochm LX; Pérez-Tapia SM; Velasco-Velázquez MA J Vis Exp; 2017 May; (123):. PubMed ID: 28518088 [TBL] [Abstract][Full Text] [Related]
19. T-Cell-Rich Recurrence of Primary Cutaneous Follicle Center Lymphoma After Systemic Rituximab: A Diagnostic Pitfall. Santonja C; Prieto-Torres L; Pérez-Sáenz MLÁ; Requena L; Rodríguez-Pinilla SM Am J Dermatopathol; 2020 Mar; 42(3):e36-e40. PubMed ID: 31592859 [TBL] [Abstract][Full Text] [Related]
20. Physician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin's Lymphoma. Huntington SF; Hoag JR; Wang R; Zeidan AM; Giri S; Gore SD; Ma X; Gross CP; Davidoff AJ J Natl Compr Canc Netw; 2019 Oct; 17(10):1194-1202. PubMed ID: 31590152 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]